

South African Rheumatism and Arthritis Association 2024 guidelines for the management of axial spondyloarthritis

A B Maharaj,^{1*} MBBS, PhD ; R Benitha,^{2*} MB ChB, MMed (Int Med); K Makan,³ MB ChB ; R du Toit,⁴ MB ChB, PhD ; D Haasbroek,⁵ MB BCh; C Balton,⁶ MB BCh ; P Govender,⁷ MB ChB, MMed (Int Med) ; M van Dam,⁸ BComm; F Paruk,⁹ MB ChB, PhD ; B Hodkinson,¹⁰ MB BCh, PhD

*ABM and RB contributed equally to this manuscript

¹ Department of Internal Medicine and Pharmacology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa

² Life Wilgeheuwel Hospital, Johannesburg, South Africa

³ Department of Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa

⁴ Division of Rheumatology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

⁵ Life Fourways Hospital, Johannesburg, South Africa

⁶ Department of Rheumatology, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

⁷ Department of Medicine, Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa

⁸ Axial Spondyloarthritis Association of South Africa, Johannesburg, South Africa

⁹ Ahmed Al-Kadi Private Hospital, Durban, South Africa

¹⁰ Division of Rheumatology, Department of Medicine, Grootte Schuur Hospital, University of Cape Town, South Africa

Corresponding author: B Hodkinson (drbridget@gmail.com)

Early diagnosis and prompt treatment initiation are essential in the management of axial spondyloarthritis (axSpA), also known as ankylosing spondylitis, remembering that underdiagnosis and overdiagnosis of axSpA are common. These South African guidelines offer screening tools and details of useful investigations, including imaging. Care of the axSpA patient requires a multidisciplinary holistic approach emphasising lifestyle interventions, particularly exercise, smoking cessation and psychosocial support. The ankylosing spondylitis disease activity score is recommended as a measure of disease activity, and a stepwise algorithm for therapy is provided. Screening for comorbidities and vaccination is advised.

Keywords: axial spondyloarthritis, South Africa

S Afr Med J 2024;114(10):e2668. <https://doi.org/10.7196/SAMJ.2024.v114i10.3469>

Axial spondyloarthritis (axSpA) is a chronic inflammatory joint disease affecting the axial skeleton, and falls within the 'family' of spondyloarthritis. Within this family, conditions including psoriatic arthritis, reactive arthritis and inflammatory bowel disease (IBD)-associated arthritis, as well as the prototype of axial disease (also referred to as ankylosing spondylitis), are found.^[1] The prevalence of axSpA usually parallels that of HLA-B₂₇ positivity.^[2-4] Prevalence and incidence data from Africa are sparse.^[3,5]

The original classification of axSpA relied on the presence of radiographic (X-ray) evidence of sacroiliitis. With the use of magnetic resonance imaging (MRI) in patients with back pain since the 1990s, inflammatory sacroiliitis was identified in patients with no features of sacroiliitis on plain X-rays, known as non-radiographic axSpA (nr-axSpA).

Peripheral joint involvement and musculoskeletal features (dactylitis, enthesitis) and extra-articular features (psoriasis, IBD and uveitis) often co-exist with axSpA, and clinicians are referred to the peripheral SpA guidelines for details of management of these problems.

Diagnosis of axSpA and screening tools

Early diagnosis and prompt treatment initiation are essential in the management of axSpA. Delays can result in higher disease burden, progressive structural damage, decreased health-related quality of life (HRQoL) and substantial economic burden, and negative outcomes regarding employability.^[6-9] Both underdiagnosis and overdiagnosis of axSpA are prevalent.^[10,11]

Screening tools for axSpA have been developed (Table 1).^[12,13] All patients with lower back pain, especially those with symptom onset aged ≤ 40 years, should be screened for inflammatory features. If present, imaging of sacroiliac joints (SIJ) and HLA-B27 antigen testing should be considered.^[14]

A clinical diagnosis of axSpA, based on the clinical presentation in combination with laboratory and imaging tests, and excluding other potentially more likely diagnoses, is the starting point. The Assessment of SpondyloArthritis International Society (ASAS) has developed classification criteria (Fig. 1) that are highly specific and sensitive.^[15,16]

Overdiagnosis of axSpA is often related to false positive MRI findings, poor awareness of the differential diagnosis of axSpA and widespread pain syndromes such as fibromyalgia.^[17-19] Mechanical causes of sacroiliitis include previous back surgery with malalignment, hypermobility with scoliosis/kyphosis, pregnancy, athletes and participants in extreme sports. Infection, particularly tuberculosis and brucellosis, must be considered.^[20]

Assessing disease activity and disability

The ankylosing spondylitis disease activity score (ASDAS) is calculated using an online calculator^[21,22] (<https://www.asas-group.org/instruments/asdas-calculator>). Based on specific cut points, disease activity can be classified into inactive disease, low, high or very high disease activity (Table 2). The ASDAS cutoff for clinically important

Table 1. Screening approach to chronic back pain. Patients with chronic low back pain (duration ≥3 months) with back pain onset <40 years of age should be referred to a rheumatologist if ≥1 of the following parameters is present

Parameter	Details
Inflammatory back pain	Any set of criteria, preferably ASAS definition of inflammatory back pain: four out of the following five parameters: (i) age at onset <40 years; (ii) insidious onset; (iii) improvement with exercise; (iv) no improvement with rest; (v) night pain with improvement upon getting up
Peripheral manifestations (arthritis, enthesitis and/or dactylitis)	Past or present, diagnosed by a physician
Extra-articular manifestations (psoriasis, inflammatory bowel disease and/or uveitis)	Past or present, diagnosed by a physician
Positive family history of SpA	Presence in first-degree or second-degree relatives of any of the following: (i) axSpA; (ii) psoriasis; (iii) acute uveitis; (iv) reactive arthritis; (v) IBD
Good response to NSAID	24 - 48 hours after a full dose of a NSAID the back pain is not present any more or is much better
HLA-B27 test	Only 5% of the general population with HLA-B27 positivity have SpA 20 - 33% of persons with chronic back pain and HLA-B27 positivity have SpA Moderate cost: done once only
Sacroiliitis on imaging, if available (X-ray or MRI)	Only if imaging is available, not recommended as routine screening parameter
Elevated acute phase reactants	CRP serum concentration or erythrocyte sedimentation rate above upper normal limit after exclusion of other causes for elevation

ASAS = Assessment of SpondyloArthritis International Society; SpA = spondyloarthritis; axSpA = axial spondyloarthritis; IBD = inflammatory bowel disease; NSAID = non-steroidal anti-inflammatory drug; HLA-B27 = human leukocyte antigen B27; MRI = magnetic resonance imaging; CRP = C-reactive protein.




Fig. 1. Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis (reproduced with permission). (SpA = spondyloarthritis; HLA-B27 = human leukocyte antigen B27; NSAIDs = non-steroidal anti-inflammatory drugs; CRP = C-reactive protein.)

*Sacroiliitis may be definite radiographically according to modified New York criteria, or by active inflammation on sacroiliac joint magnetic resonance imaging showing clear presence of bone marrow oedema or osteitis.

improvement between examinations is ≥1.1, and the cutoff for a major improvement is ≥2.0. An alternative to the ASDAS is the Bath ankylosing spondylitis disease activity index (BASDAI),^[23] with a score ≥4/10 considered 'active' disease, with a change of ≥50% in the BASDAI reflecting a clinically relevant improvement.^[24] The Bath ankylosing spondylitis functional index (BASFI) measures functional disability in 10 different areas based on a visual analogue scale of 0 - 10.^[25]

Radiography

Pelvic X-rays

The modified New York criteria describe the grading of the SIJ on pelvic X-rays.^[26,27]

Sclerosis, erosions, joint space widening or ankylosis of SIJ are features of established disease, and may take years to develop. Changes compatible with a classification of axSpA are grade 2 (or higher) changes bilaterally or grade 3 (or higher) unilaterally. Degenerative changes of SIJ are common.

Magnetic resonance imaging

A non-contrast MRI of the SIJs is key to diagnosing early disease, as it is more specific and sensitive than plain radiographs. Interpretation of MRI by a radiologist with expertise in axial imaging is recommended. A 'positive MRI' has the following requirements:

- bone marrow oedema (BMO) on a T2-weighted sequence sensitive for free water (such as short tau inversion recovery (STIR) or T2FS) or bone marrow contrast enhancement on a T1-weighted sequence (such as T1FS post-Gd)
- inflammation clearly present and located in a typical anatomical area (subchondral bone)
- MRI appearance must be highly suggestive of SpA.

Management principles

Patient information and decision-making

The aim of treatment is to maintain a good quality of life and function, including social participation. There is strong evidence that uncontrolled disease leads to radiographic progression, and that physical disability is a result of high disease activity and structural damage.^[28-30] Importantly, there is now a choice of therapies to control inflammation in axSpA. Control of active disease can lead to improvements in physical function, HRQoL and work productivity.^[31]

A management plan should be developed based on shared decision-making between patients and clinicians, according to the patient's values, goals, preferences and comorbidities. Patient education should offer information about axSpA and its complications, including disease assessment modalities, treatment goals, medications and adherence. A rheumatology nurse can offer patient education and support, with positive effects on adherence to therapy and on HRQoL.^[32-34] Treatment should be individualised according to patient charac-

teristics, clinical features including extra-articular features, comorbidities and psychosocial factors.

Interventions including pharmacological therapy, physical activity, disease-related problem-solving, emotional wellbeing, communication skills and use of community resources, including patient support organisations, should be emphasised.

Referral to a rheumatologist and multidisciplinary team

All axSpA patients should ideally be seen by a rheumatologist, particularly those with diagnostic uncertainty, persistent moderate or high disease activity, functional impairment, or extra-articular disease. Care of the axSpA patient requires a multidisciplinary holistic approach that might include a dermatologist, gastroenterologist, ophthalmologist, occupational therapist, podiatrist, physiotherapist, biokineticist, pain specialist, clinical psychologist or social worker, as appropriate.

Lifestyle interventions and work participation

The importance of a healthy lifestyle, including smoking cessation, physical therapy and participation in patient support groups should be encouraged.^[35-37] Exercise is a cornerstone in the management of axSpA, with demonstrated benefits on disease outcomes independent of pharmacological treatment.^[35,38-40] Work participation may have positive effects on health outcomes, and SpA patients should be encouraged to continue formal or informal work.^[41]

Comorbidities and extra-articular disease

The majority of axSpA patients have ≥ 1 comorbidity leading to premature mortality, functional impairment and reduced HRQoL.^[42] Accelerated atherosclerosis and cardiovascular events, infections and osteoporosis are the major comorbidities in axSpA, and need regular screening and evidence-based management.^[43] Additional comorbidities include chronic fatigue, depression, anxiety, degenerative joint disease, hypertension, dyslipidaemia, obesity and central pain sensitisation syndromes such as fibromyalgia syndrome.^[44]

Screening for hepatitis B, hepatitis C, HIV and tuberculosis should be done at presentation, and repeated as clinically indicated. The vaccination status, pregnancy plans, contraception and lactational status (if relevant) of the patient should be regularly reviewed and discussed.

Therapy of axSpA

Goal of therapy

The goal of therapy is to achieve remission (ASDAS < 1.3), or at least low disease activity (ASDAS < 2.1).

Details of therapies

Disease-modifying antirheumatic drugs (DMARDs)

These agents are divided into three broad groups: conventional synthetic (cs) DMARDs, biologic (b) DMARDs and targeted synthetic (ts) DMARDs. The bDMARDs are either biologic original (bo) DMARDs or biosimilar (bs) DMARDs, and include:

- tumour necrosis factor inhibitors (TNFi): either receptor blockers (etanercept (original and biosimilar) or monoclonal antibodies (infliximab (original and biosimilar)); adalimumab (original and biosimilar) and golimumab
- IL-17 inhibitors (IL-17i) (secukinumab and ixekizumab).

The tsDMARDs include the Janus kinase (JAK) inhibitors tofacitinib and upadacitinib. Baricitinib, a JAK2 inhibitor, is not currently approved for axSpA therapy.

Glucocorticoids

Patients with axial involvement should not receive long-term systemic glucocorticoids (GCs). If required, local injections of GCs at sites of inflammation may be considered.^[45] Of note, GC injections into the achilles or patella tendons is associated with a risk of tendon rupture.

Non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) are first-line therapy for axSpA, and the response is usually excellent. The toxicity of these drugs should not be underestimated, and all NSAIDs should be used with caution. Many axSpA patients have risk factors for NSAID-induced gastrointestinal tract events, including older age (> 60 years), as well as co-prescription of aspirin. Hence, there should be a low threshold for co-prescribing a proton pump inhibitor for gastro protection, or for considering a cyclooxygenase-2 (COX-2) selective agent.^[46] In addition, all NSAIDs, both non-selective agents and selective COX-2 inhibitors, confer an increased risk of thrombotic events, and should be used with caution in patients with cardiovascular (CV) risk factors, although the CV risk induced by NSAIDs in axSpA remains controversial. Other side-effects of NSAIDs, including hypertension, renal and liver dysfunction, should not be forgotten. Analgesics such as paracetamol or opioids might be considered if there is an incomplete response to NSAIDs, or NSAIDs are contraindicated.

Sequential therapy for axSpA (Table 3)

First-line therapy: NSAIDs

Patients with predominantly axial manifestations associated with pain and stiffness should be commenced on an NSAID as first-line therapy provided there are no contraindications. The maximum recommended/tolerated dose should be titrated to response, side-effect profile and patient risk factors. A 2 - 4-week trial is recommended. If the response is poor, an alternate NSAID should be prescribed. Whether NSAIDs can retard radiographic progression (growth of syndesmophytes in the spine) in axSpA patients is controversial.^[47-50] For patients who respond well to NSAIDs, continuous treatment is advised with appropriate monitoring.

Second-line therapy (if peripheral arthritis): Conventional synthetic disease-modifying drugs

Patients with purely axial disease should not be treated with csDMARDs as there is no evidence to support their use in axial disease.^[51,52]

Sulphasalazine may be considered for patients with peripheral arthritis.^[53] While there is no evidence to support the use of methotrexate (MTX) or leflunomide in patients with peripheral manifestations, they may be used in exceptional situations where other pharmacological treatment options are not available.

For extra-articular manifestations of axSpA, including psoriasis, uveitis and inflammatory bowel disease, csDMARDs may be beneficial (see 'Guidelines for the management of peripheral SpA' for details).

Third- and fourth-line therapy: b/tsDMARD therapy

South African Rheumatism and Arthritis Association (SARAA) eligibility criteria for b/tsDMARD therapies for axSpA:

- A diagnosis of definite axSpA made by a rheumatologist according to ASAS criteria
- Objective evidence of inflammation:
 - elevated C-reactive protein (CRP), or
 - MRI evidence of active sacroiliitis, or

- ultrasound evidence of inflammation in the joint/enthesitis/dactylitis.
- Sustained high disease activity for two visits at least 4 weeks apart defined by:
 - ASDAS score of >2.1
 - spinal pain visual analogue scale (1 - 10 cm) ≥4.
- Failure of standard treatment:
 - at least two NSAIDs during a 4-week period
 - if peripheral arthritis, failure of sulfasalazine.
- Refractory enthesitis, uveitis or other extra-articular manifestations.

Choice of b/tsDMARD

There are, to date, no validated biomarkers or head-to-head studies of b/tsDMARD in axSpA to guide choice of biological agent in axSpA. On a group level, there are no differences in the efficacy of various TNFi for axSpA itself, but there are differences on an individual patient level, which remain poorly understood.^[54] The choice of b/tsDMARD therapy depends on which SpA domain is involved, extra-articular disease, patient preference, tuberculosis risk, comorbidities, route of administration and cost. Details are offered in the peripheral SpA guidelines.

If the patient has extra-articular manifestations of uveitis or IBD, then monoclonal TNFi is preferred, and the soluble receptor (etanercept) should be avoided. Similarly, IL-17i and JAKi have not been shown to be efficacious in uveitis. IL-17i should not be used in patients with active IBD.^[55] IL 12/23 inhibitors are not effective for axSpA. Baricitinib, a JAK2 inhibitor, is not currently approved for axSpA therapy.

The use of combination b/tsDMARDs is not recommended.

In SpA (axial or peripheral), there is little evidence that co-prescription of MTX with b/tsDMARDs is necessary.

All b/tsDMARDs should be initiated by a rheumatologist. All patients with a rheumatic disease on b/tsDMARDs must be included, with patient consent, in the SARAA biologics registry (<https://www.saraa.co.za>). Before commencing b/tsDMARD, appropriate screening and treatment for latent tuberculosis, hepatitis B, hepatitis C and HIV, in addition to vaccination, should be done.

The patient should be evaluated at 3 months to assess the response to treatment. If there is an improvement of the ASDAS ≥1.1 and/or BASDAI ≥2, treatment should be continued. In the case of inadequate response to therapy, the patient needs review in terms of diagnosis of axSpA, structural damage v. active disease-causing symptoms (consider CRP and/or MRI scan) and adherence to therapy.

Tapering of bDMARDs

If the patient has a good response to therapy with sustained remission for a period of 6 months (ASDAS <1.3 and normal CRP on three consecutive visits or for 6 months), tapering of the bDMARDs might be considered in a shared decision-making process.^[56,57] Tapering should either be in the form of reduction of dose or increasing the interval of administration. Tapering should be done slowly and cautiously to prevent any flares in disease. Discontinuation is not advised, as the evidence shows that a high proportion of patients experience disease flares.^[58]

Special notes on comorbidities

Osteoporosis and spinal fracture

Screening for osteoporosis is recommended as per local protocol, remembering that sclerosis of the axial skeleton may make dual X-ray absorptiometry (DEXA) scan interpretation difficult – therefore DEXA of the wrist and hip (if unaffected by ankylosis) is recommended. Alternatively, dual-energy quantitative computed tomography may be used to assess the patient. Recently, the trabecular bone score mapping of L1-L4 derived from the DEXA image has been shown to be related to bone micro-architecture and fracture risk.^[59]

If any significant changes in the patient’s pain/backache occur and the nature of the pain changes from inflammatory to mechanical, spinal fractures should be considered, and appropriate imaging and treatment are advised.^[60] Risk factors for spinal fracture in axSpA include advanced age, higher BASFI, longer disease duration, low bone mineral density and osteoporosis.

Response to therapy

Table 2. Disease activity assessment tools and cutpoints for axial spondyloarthritis

Cutpoint	Ankylosing spondylitis disease activity score (ASDAS)	Bath ankylosing spondylitis disease activity index (BASDAI)
Inactive disease	<1.3	<1.6
Low disease activity	<2.1	<2.9
High disease activity	<3.5	<3.8
Very high disease activity	≥3.5	≥3.8
Online calculator	https://www.asas-group.org/instruments/asdas-calculator	https://www.bas dai.com/BASDAI.php

Table 3. Stepwise algorithm for therapy in axial spondyloarthritis

Step	Therapy	Inadequate response within 3 months
First-line therapy	NSAID	Proceed to second-line therapy
Second-line therapy (if peripheral arthritis)	Sulfasalazine 2 - 3 g/daily	Proceed to third-line therapy
Third-line therapy	b/tsDMARD (TNFi/IL-17i/JAKi)	Proceed to fourth-line therapy
Fourth-line therapy	Alternative b/tsDMARD (TNFi/IL-17i/JAKi)	
Tapering	Consider tapering if sustained remission × 6 months	Restart b/tsDMARD if flares

NSAID = non-steroidal anti-inflammatory drug; b/tsDMARD = biologic/targeted synthetic disease-modifying antirheumatic drug; TNFi = tumour necrosis factor inhibitor; IL-17i = interleukin-17 inhibitor; JAKi = Janus kinase inhibitor.

Summary points pertaining to the management of axSpA

Early diagnosis and prompt treatment initiation are essential in the management of axSpA, using the ASAS classification criteria as a reference. Both under-diagnosis and over-diagnosis are prevalent. Management by a rheumatologist-led multidisciplinary team should include pharmacological therapy, physical activity and referral to a patient support organisation. The goal of therapy is to achieve remission (ASDAS <1.3), or at least low disease activity (ASDAS <2.1). Sequential therapy should be offered until this goal is achieved. Screening and management of comorbidities including cardiovascular disease, infections, osteoporosis and depression should be undertaken.

axSpA = axial spondyloarthritis; ASAS = Assessment of SpondyloArthritis International Society; ASDAS = ankylosing spondylitis disease activity score.

1. Schwartzman S, Ruderman EM. A road map of the axial spondyloarthritis continuum. *Mayo Clinic Proc* 2022;97(1):134-145. <https://doi.org/10.1016/j.mayocp.2021.08.007>
2. Slimani S, Hamdi W, Nassar K, Kalla AA. Spondyloarthritis in North Africa: An update. *Clin Rheumatol* 2021;40:3401-3410. <https://doi.org/10.1007/s10067-021-05630-w>
3. Tikly M, Njobvu P, McGill P. Spondyloarthritis in sub-Saharan Africa. *Curr Rheumatol Rep* 2014;16:421. <https://doi.org/10.1007/s10067-021-05630-w>
4. Sheehan NJ. The ramifications of HLA-B27. *J Royal Soc Med* 2004;97(1):10-14.
5. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. *Rheumatology* 2014;53(4):650-657.
6. Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: A systematic review. *Rheumatol Ther* 2020;7(1):65-87. <https://doi.org/10.1007/s40744-020-00194-8>.
7. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. *Semin Arthritis Rheum* 2015;44(5):556-562. <https://doi.org/10.1016/j.semarthrit.2014.10.009>
8. Ward MM. Quality of life in patients with ankylosing spondylitis. *Rheumatic Dis Clin North Am* 1998;24(4):815-827.
9. Martindale J, Shukla R, Goodacre J. The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. *Best Pract Res Clin Rheumatol* 2015;29(3):512-523. <https://doi.org/10.1016/j.berh.2015.04.002>
10. Landewé RB. Overdiagnosis and overtreatment in rheumatology: A little caution is in order. *Ann Rheumatol Dis* 2018;77(10):1394-1396. <https://doi.org/10.1136/annrheumdis-2018-213700>
11. Bittar M, Khan MA, Magrey M. Axial spondyloarthritis and diagnostic challenges: Over-diagnosis, misdiagnosis, and under-diagnosis. *Curr Rheumatol Rep* 2023;25(3):47-55. <https://doi.org/10.1007/s11926-022-01096-0>
12. Poddubnyy D, van Tubergen A, Landewé R, Sieper J, van der Heijde D. Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. *Ann Rheumatol Dis* 2015;74(8):1483-1487.
13. Ozgocmen S, Akgul O, Khan MA. Mnemonic for assessment of the spondyloarthritis international society criteria. *J Rheumatol* 2010;37(9):1978. <https://doi.org/10.3899/jrheum.100477>
14. Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. *Autoimmunity Rev* 2009;8(5):420-425.
15. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. *Ann Rheumatol Dis* 2009;68(6):777-783.
16. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. *Ann Rheumatol Dis* 2017;76(5):886-890.
17. Sepriano A, Ramiro S, van der Heijde D, et al. What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. *Ann Rheumatol Dis* 2020;79(3):324-331.
18. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. *Ann Rheumatol Dis* 2021;80(12):1511-1521.
19. Rudwaleit M. Fibromyalgia is not axial spondyloarthritis. *Rheumatology* 2018;57(9):1510-1512. <https://doi.org/10.1093/rheumatology/keu372>
20. Campos-Correia D, Sudol-Szopinska I, Afonso D. Are we overcalling sacroiliitis on MRI? Differential diagnosis that every rheumatologist should know-Part I. *Acta Reumatologica Portuguesa* 2019;44(1):29-41.
21. Van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheumatol Dis* 2009;68(12):1811-1818.
22. Machado P, Landewé R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): Refining cut-off values for disease activity states and improvement scores. *Ann Rheumatol Dis* 2011;70(1):47-53. <https://doi.org/10.1136/ard.2010.138594>
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index. *J Rheumatol* 1994;21(12):2286-2291.
24. Cui R, Du Y, Tian N, Jiang H-L, Tao Y-L, Dai S-M. Equivalent cut-off values of Bath ankylosing spondylitis disease activity index corresponding to ankylosing spondylitis disease activity score cut-off values. *Clin Exp Rheumatol* 2023;41(5):1163-1169. <https://doi.org/10.55563/clinexp/2023/23jg2>
25. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath ankylosing spondylitis functional index. *J Rheumatol* 1994;21(12):2281-2285.
26. Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. *Arthr Rheumatism* 1984;27(4):361-368.
27. Lambert RG, Bakker PA, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI working group. *Ann Rheumatol Dis* 2016;75(11):1958-1563.
28. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. *Ann Rheumatol Dis* 2014;73(8):1455-1461.
29. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. *Ann Rheumatol Dis* 2009;68(6):863-867.
30. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the GERman SPondyloArthritis Inception Cohort. *Ann Rheumatol Dis* 2016;75(12):2114-2118.

31. Van der Heijde D, Joshi A, Pangan AL, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. *Rheumatology* 2016;55(1):80-88.
32. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. *Ann Rheum Dis* 2015;74(6):954-962.
33. Sudre A, Figueredo IT, Lukas C, Combe B, Morel J. On the impact of a dedicated educational program for ankylosing spondylitis: Effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. *Joint Bone Spine* 2011;79(1):99-100.
34. Candelas G, Villaverde V, García S, Guerra M, León M, Cañete J. Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review. *Rheumatol Int* 2016;36(11):1493-1506. <https://doi.org/10.1007/s00296-016-3549-5>
35. Dagfinrud H, Hagen KB, Kvien TK. Physiotherapy interventions for ankylosing spondylitis. *Cochrane Database Syst Rev* 2008;(1):CD002822. <https://doi.org/10.1002/14651858.CD002822.pub3>
36. Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthritis: Unravelling the complexities. *Rheumatology* 2020;59(7):1472-1481. <https://doi.org/10.1093/rheumatology/keaa093>
37. Roberts MJ, Leonard AN, Bishop NC, Moorthy A. Lifestyle modification and inflammation in people with axial spondyloarthritis - a scoping review. *Musculoskel Care* 2022;20(3):516-528. <https://doi.org/10.1002/msc.1625>
38. Ortolan A, Webers C, Sepriano A, et al. Efficacy and safety of non-pharmacological and non-biological interventions: A systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. *Ann Rheumatol Dis* 2023;82(1):142-152. <https://doi.org/10.1136/ard-2022-223297>
39. Osthoff A-KR, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. *Ann Rheumatol Dis* 2018;77(9):1251-1260. <https://doi.org/10.1136/annrheumdis-2018-213585>
40. Nouredin B, Barkham N. The current standard of care and the unmet needs for axial spondyloarthritis. *Rheumatology* 2018;57(Suppl 6):vi10-vi17. <https://doi.org/10.1093/rheumatology/key217>
41. Hoving JL, Lacaille D, Urquhart DM, Hannu TJ, Sluiter JK, Frings-Dresen MH. Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis. *Cochrane Database Syst Rev* 2014;6:2014(11):CD010208. <https://doi.org/10.1002/14651858.CD010208.pub2>
42. Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: Systematic review and meta-analysis. *Rheumatology* 2020;59(Suppl_4):iv47-iv57. <https://doi.org/10.1093/rheumatology/keaa246>
43. Bodur H. Cardiovascular comorbidities in spondyloarthritis. *Clin Rheumatol* 2022;1-10. <https://doi.org/10.1007/s10067-022-06473-9>
44. Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheumatol Dis* 2016;75(6):1016-1023. <https://doi.org/10.1136/annrheumdis-2015-208174>
45. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: Results of a double-blind, randomised, placebo-controlled short-term trial. *Ann Rheumatol Dis* 2014;73(1):243-246. <https://doi.org/10.1136/annrheumdis-2012-203055>
46. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. *Am J Gastroenterol* 2008;103(11):2908-2918. <https://doi.org/10.1111/j.1572-0241.2008.02200.x>
47. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1. *Ann Rheumatol Dis* 2014;73(1):101-107. <https://doi.org/10.1136/annrheumdis-2012-203201>
48. Wanders A, Heijde Dvd, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomised clinical trial. *Arthr Rheumatism* 2005;52(6):1756-1765. <https://doi.org/10.1002/art.21054>
49. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann Rheumatol Dis* 2012;71(10):1623-1629. <https://doi.org/10.1136/annrheumdis-2012-201370>
50. Hintenberger R, Affenzeller B, Vladychuk V, Pieringer H. Cardiovascular risk in axial spondyloarthritis - a systematic review. *Clin Rheumatol* 2023;42(10):2621-2633. <https://doi.org/10.1007/s10067-023-06655-z>
51. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev* 2013;(2):CD004524. <https://doi.org/10.1002/14651858.CD004524.pub4>
52. Haibel H, Brandt H, Song I, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. *Ann Rheumatol Dis* 2007;66(3):419-421. <https://doi.org/10.1136/ard.2006.054098>
53. Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. *Cochrane Database Syst Rev* 2014;2014(11):CD004800. <https://doi.org/10.1002/14651858.CD004800.pub3>
54. Wang R, Dasgupta A, Ward MM. Comparative efficacy of tumor necrosis factor- α inhibitors in ankylosing spondylitis: A systematic review and Bayesian network metaanalysis. *J Rheumatol* 2018;45(4):481-490. <https://doi.org/10.3899/jrheum.170224>
55. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. *Gut* 2012;61(12):1693-1700. <https://doi.org/10.1136/gutjnl-2011-301668>
56. Yates M, Hamilton LE, Elender F, et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomised control trial. *J Rheumatol* 2015;42(7):1177-1185. <https://doi.org/10.3899/jrheum.141335>
57. Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomised, prospective, long-term, follow-up study. *Biologics* 2013;7:1-6. <https://doi.org/10.2147/BTT.S31474>
58. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. *Arthr Rheumatism* 2013;65(8):2211-2213. <https://doi.org/10.1002/art.38014>
59. Richards C, Leslie WD. Trabecular bone score in rheumatic disease. *Curr Rheumatol Rep* 2022;24(4):81-87. <https://doi.org/10.1007/s11926-022-01062-w>
60. Westerveld L, Verlaan J, Oner F. Spinal fractures in patients with ankylosing spinal disorders: A systematic review of the literature on treatment, neurological status and complications. *Eur Spine J* 2009;18(2):145-156. <https://doi.org/10.1007/s00586-008-0764-0>

Received 20 August 2023; accepted 8 August 2024.